报价延迟最少15分钟:2025/11/16 02:43 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.86 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.23/0.12
|
|
企业价值
1.57B
|
| 资产负债 |
|
每股账面净值
0.64
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
333.62M
|
|
每股收益
0.55
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 02:43 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adultswith IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. |
